Metraipolis › archive › dc_fe4553d306e2

AIDSVAX — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/AIDSVAX
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-07T00:06:35.913Z
SHA-256 of the archived text
e2eef818fb9ba9414d9e35d3cebdf54641c4e190d0e7bb897b8ab8c23f4dde3d
Stable URL of this page
https://metraipolis.com/documento/dc_fe4553d306e2

How to cite

AIDSVAX — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/AIDSVAX (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_fe4553d306e2 (Metraipolis archive dc_fe4553d306e2, sha256 e2eef818fb9ba9414d9e35d3cebdf54641c4e190d0e7bb897b8ab8c23f4dde3d)
BibTeX
@misc{dcfe4553d306e2,
  title = {AIDSVAX — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/AIDSVAX},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_fe4553d306e2; sha256 e2eef818fb9ba9414d9e35d3cebdf54641c4e190d0e7bb897b8ab8c23f4dde3d},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/AIDSVAX. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

AIDSVAX is an experimental HIV vaccine that was developed originally at Genentech in San Francisco, California, and later tested by the VaxGen company, a Genentech offshoot. The development and trials of the vaccine received significant coverage in the international media, but American trials proved inconclusive. The vaccine was then tested on a group of at-risk individuals in Thailand. In 1991, AIDSVAX originally consisted of the B envelope of recombinant gp120, a glycoprotein unique to HIV's surface, from a strain of the virus, MN, known at the time to infect people in the United States and Europe. The vaccine was designed to provoke the production of antibodies in subjects that would strip the gp120 protein off of the HIV viral particles, effectively disabling the virus so that it could not bind to or invade susceptible cells. Then, another group, infected with a second strain of HIV, A244, was discovered in 1995, and a revised, bivalent version of the vaccine was produced that combined elements of both MN and A244. Phase I and Phase II tests of the first version were promising, showing excellent safety in chimpanzees and humans and provoking production of HIV MN and A244 antibodies in 99% of human volunteers. VaxGen's leadership enthusiastically applied to the U.S. Food and Drug Administration (FDA) for permission to undertake Phase III studies in the U. S. on large numbers of at-risk volunteers. But since some of the Phase I and Phase II volunteers had become infected with HIV while taking the vaccine, showing that the vaccine was not 100% effective, and it was not proven that the vaccine itself hadn't caused these infections, the FDA and other members of the medical community hesitated and finally declined to approve Phase III testing "until more was learned about HIV immunity", although early versions of successful vaccines have rarely been 100% effective, and even the 1955 Salk polio vaccine was only 70% effective, superseded as it was seven years later by the Sabin vaccine. With human lives at stake, however, the FDA could not risk condoning further trials until it knew what had caused the infections. Another problem with AIDSVAX was that it provoked an entirely humoral, antibody immune response in its subjects, unlike other HIV vaccines in development in Europe and elsewhere that were provoking balanced antibody and cellular defenses. In response, VaxGen turned to the international community, seeking a place that would sanction clinical trials of AIDSVAX, and after negotiating with AIDS-plagued officials in Africa and Asia, landed upon Thailand. Initial Phase II trials of AIDSVAX B/B alone in the US and AIDVAX B/E alone in Thailand were unsuccessful, with both vaccines failing to either prevent or weaken HIV infection, so instead VaxGen began Thai trials of AIDSVAX B/E in combination with the Aventis-Pasteur vaccine, ALVAC-HIV, that uses genetic elements of several different HIV strains encapsulated in a canarypox virus vector. AIDSVAX 

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «AIDSVAX» — https://en.wikipedia.org/wiki/AIDSVAX
Wikidata Q16002131: «experimental vaccine developed by Genentech against Human Immunodeficiency Virus (HIV)» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q16002131
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/AIDSVAX?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1299869966, consultata il 2026-11-07T00:03:01.138Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: f30e906ec4339cf38e9c70b6206e4bbf855e1921b9da79c95b3a93152a9faa65